180 Wealth Advisors LLC Has $200,000 Holdings in Recursion Pharmaceuticals, Inc. $RXRX

180 Wealth Advisors LLC grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 37.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,430 shares of the company’s stock after buying an additional 10,665 shares during the period. 180 Wealth Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $200,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth about $36,000. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter worth about $51,000. ADG Wealth Management Group LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth about $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth about $57,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Transactions at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider directly owned 668,197 shares in the company, valued at $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 8.43% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Trading Up 5.4%

Shares of RXRX opened at $6.04 on Friday. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -3.39 and a beta of 0.91. The stock’s 50-day moving average price is $5.18 and its 200 day moving average price is $5.19.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. The company’s revenue was up 33.3% on a year-over-year basis. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

RXRX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Saturday. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.